Mark Dawson is a clinician-scientist whose research focuses on studying the biological mechanisms by which epigenetic regulators facilitate the induction, maintenance and progression of cancer. His innovative research program has provided several paradigm shifting discoveries into epigenetic mechanisms of cancer stem cell maintenance, resistance to anti-cancer therapies and regulation of anti-cancer immune surveillance. His research has directly contributed to the development of several first-in-class epigenetic therapies, including those that have been studied in more than 30 clinical trials across at least 20 countries. His leading international reputation is evidenced by his publications, grant funding, invitations to speak and the receipt of prestigious prizes and awards for his research.